The CONNECT trial found greater A1C reductions and more time in target glucose range among adults using continuous glucose monitoring.

New study finds continuous glucose monitors improve blood sugar control in people with type 2 diabetes who don't use insulin.

DexCom (NasdaqGS:DXCM) reported that results from the CONNECT randomized controlled trial of its G7 CGM were published in The ...

Adults with type 2 diabetes who don't use insulin lowered their A1C by 0.9 percentage points more with a continuous glucose monitor (CGM) than with routine care over 26 weeks, according to results ...

Continuous glucose monitoring (CGM) leads to a greater reduction in glycated hemoglobin (HbA1c) levels than routine care for ...

(ISIN US2521311074) plans to release its third-quarter 2026 results on October 29, 2026, making the next earnings report the ...

Abbott Laboratories (NYSE:ABT) benefits each time a patient replaces a glucose sensor. Continuous glucose monitoring, or CGM, ...

DXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with ...

College athletics has seen a lot of changes over the last few years with one of the biggest being student athletes ability to ...

Continuous glucose monitors can dramatically improve blood sugar control among people with type 2 diabetes who aren’t yet ...

South Korea's CGM market reached 57.5 billion won in 2024, with imports holding 92.5% as Daewoong, Huons and i-SENS compete.

A wearable blood sugar monitor may help people with type 2 diabetes even when they don’t need insulin. In a newly published clinical trial, adults using the Dexcom G7 achieved significantly better ...